The Pfizer-BioNTech COVID-19 vaccine candidates were tested in a three-phase clinical trial in 2020, registered on ClinicalTrials.gov with identifying number C4591001.[1]
The list of investigators was published as a Supplementary Appendix.[2]
There were 169 official clinical trial sites listed on the trial's ClinicalTrials.gov listing.[1:1] Organizations that served as clinical trial sites included:
BioNTech SE, & Pfizer. (2023, February 28). Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals. ClinicalTrials.gov. https://web.archive.org/web/20230420203001/https://clinicaltrials.gov/ct2/show/NCT04368728 ↩︎ ↩︎
Supplementary Appendix (p. 2). (2021). medRxiv. https://web.archive.org/web/20230826041437/https://www.medrxiv.org/content/medrxiv/early/2021/07/28/2021.07.28.21261159/DC1/embed/media-1.pdf ↩︎